Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Enrolling by invitation 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 665Neoplasms 585Colorectal Neoplasms 291Carcinoma, Non-Small-Cell Lung 289Prostatic Neoplasms 277Lung Neoplasms 217Melanoma 159Multiple Myeloma 149Neoplasm Metastasis 145Head and Neck Neoplasms 143Pancreatic Neoplasms 139Ovarian Neoplasms 129Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 121Brain Neoplasms 111Squamous Cell Carcinoma of Head and Neck 109Colonic Neoplasms 109Uterine Cervical Neoplasms 106Stomach Neoplasms 102Recurrence 101Lymphoma 100Glioblastoma 90Lymphoma, Non-Hodgkin 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 78Hematologic Neoplasms 78Lymphoma, Follicular 77Urinary Bladder Neoplasms 76Parkinson Disease 4, Autosomal Dominant Lewy Body 74Glioma 72Sarcoma 70

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuromuscular Diseases × 1 year × Clear all
NCT05451212 2025-11-10

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Cabaletta Bio

Phase 1 Completed
7 enrolled

Autoimmune Diseases, Immune System Diseases, Musculoskeletal Diseases, Myasthenia Gravis, Neuromuscular Diseases, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡